TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35612684
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg-1, OP-CAF)
Study: 32446323
Drug: Comprehensive disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, SGLT2 inhibitor)
Study: 39077886
Drug: Bimekizumab 160
Normalized name: Bimekizumab 160 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 160 mg every four weeks
Study: 33044249
Drug: Allogeneic pure
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic pure PRP injection (4 mL)
Study: 33044249
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (4 mL mixture of 1 mL of 40‐mg/mL triamcinolone acetonide and 3 mL of 2% lidocaine)
Study: 33044249
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (4 mL mixture)
Study: 33922552
Drug: Fentanyl administration
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl administration
Study: 33922552
Drug: Sevoflurane administration
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administration
Study: 34255767
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on cerebrospinal fluid (CSF) analysis after lumbar puncture (LP)
Study: 33685394
Drug: Topical tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tissue adhesive (TA)
Study: 35034023
Drug: Titration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration group (Adinox® 25 mg aspirin/200 mg dipyridamole once daily for 2 weeks, then twice daily for 2 weeks)
Study: 35034023
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (Adinox® twice daily for 4 weeks)
Study: 35034023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Aspirin 100 mg once daily for 4 weeks)
Study: 38841588
Drug: DAPT (Dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (Dual Antiplatelet Therapy)
Study: 33675664
Drug: Levofloxacin administration
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administration
Study: 32454920
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg/kg intravenous bolus injection for 10 min before induction of anesthesia, followed by continuous infusion of 0.2‐0.4 μg/kg/h until the end of surgery, and 0.06 μg/kg/h for 5 days after surgery)
Study: 33203618
Drug: Oral beta
Normalized name: Cloral betaine
DrugBank: Chloral betaine (DB01494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta blockade
Study: 33203618
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker and ACEI/ARB
Study: 33203618
Drug: Neither ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither ACEI/ARB nor beta blocker
Study: 34024196
Drug: Orchid drug-coated
Normalized name: Orchis mascula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchid drug-coated balloon (coated with paclitaxel)
Study: 33985991
Drug: Lumasiran (0.3-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumasiran (0.3-6 mg/kg single dose for healthy participants; up to 3 doses of 1 or 3 mg/kg monthly or 3 mg/kg quarterly for patients)
Study: 32746825
Drug: Involvement in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement in treatment of palliative patients after SPHC initiation
Study: 34992754
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural grief therapy (ICBGT)
Study: 34736438
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with intravenous S-ketamine
Study: 35300564
Drug: Lacticaseibacillus paracasei
Normalized name: Lacticaseibacillus paracasei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus paracasei N1115 (2×10^10 cfu/g, 2 g/day)
Study: 35300564
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 2 g/day)
Study: 39651334
Drug: Sham TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TENS treatment
Study: 32945739
Drug: Inoculated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculated with Ralstonia solanacearum species complex (RSSC) phylotype I strain GMI1000 at a concentration of 10^8 CFU/mL, using soil soak method.
Study: 33942563
Drug: Culturally informed
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally informed treatment based on Intervention Mapping (IM); 4 sessions, each under 1 hour
Study: 34784124
Drug: 1927 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1927 nm thulium fiber laser with 0.05% tretinoin lotion
Study: 34784124
Drug: Vehicle group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle group (no tretinoin lotion)
Study: 33545764
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (Ensure®) daily in addition to daily routine diets after discharge
Study: 33621471
Drug: 4-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose intramuscular Essen regimen
Study: 33621471
Drug: 5-dose intramuscular
Normalized name: PAXLOVID 300 MG ; 100 MG (Day 1), 150 MG ; 100 MG (Days 2-5) Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-dose intramuscular Essen regimen
Study: 35589854
Drug: Tocilizumab (anti-IL6R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (anti-IL6R monoclonal antibody)
Study: 34031690
Drug: Second-source verification
Normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-source verification conducted on PTA medication list
Study: 35083924
Drug: FOCUS4-B (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOCUS4-B (Aspirin in PIK3CA mutant subgroup)
Study: 35083924
Drug: FOCUS4-N (Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOCUS4-N (Capecitabine monotherapy)
Study: 34147123
Drug: Random allocation
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random allocation to treatment (control group)
Study: 35094258
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of celecoxib
Study: 35094258
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of celecoxib
Study: 32456230
Drug: Tocovid (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocovid (200 mg twice a day)
Study: 35986358
Drug: Livogen Plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livogen Plus® (nutraceutical) - 6 softgel capsules daily for 12 weeks
Study: 35986358
Drug: Placebo (maltodextrin)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin) - 6 softgel capsules daily for 12 weeks
Study: 34905434
Drug: Cultural Formulation
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultural Formulation Interview (CFI+AAU)
Study: 33228827
Drug: Thyme (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme (20 g/head/day)
Study: 33228827
Drug: Celery (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celery (20 g/head/day)
Study: 33228827
Drug: Thyme +
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme + Celery (10 g each/head/day)
Study: 33228827
Drug: Salinomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salinomycin (1 g/head/day)
Study: 35614482
Drug: Artesunate 100
Normalized name: Artesunate 100 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 100 mg
Study: 35614482
Drug: Artesunate 50
Normalized name: artesunate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 50 mg
Study: 33947587
Drug: Care pathway
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care pathway treatment
Study: 36316841
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy of traditional Chinese medicine (CTTCM)
Study: 34718403
Drug: Drug withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug withdrawal (DW)
Study: 34157349
Drug: Early intubation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intubation for surfactant administration
Study: 34172029
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT), delivered in five sessions, in-person
Study: 34732099
Drug: Bright blue-green
Normalized name: BLUE GREEN ALGAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright blue-green light therapy (experimental group)
Study: 34732099
Drug: Dim red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red light therapy (control group)
Study: 34092586
Drug: Apis dorsata
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apis dorsata Honey (13 ml, 1 tablespoon × 3 for 15 days)
Study: 35264321
Drug: Mavrilimumab 150
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrilimumab 150 mg subcutaneously every 2 weeks with 26-week prednisone taper
Study: 38279390
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 26-week prednisone taper
Study: 32337932
Drug: Parental preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental preparation for dental visits (self-preparation)
Study: 32337932
Drug: Parental reliance
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental reliance on dentists for preparation
Study: 32337932
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of parent's dental anxiety and pre-appointment preparation with children's dental fear
Study: 36402666
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser acupuncture treatment (control)
Study: 34724251
Drug: Roxadustat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 2.5 mg/kg
Study: 34724251
Drug: Roxadustat 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat 1.5 mg/kg and 2.0 mg/kg
Study: 34724251
Drug: Roxadustat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (all doses)
Study: 33962841
Drug: NDV-3A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDV-3A vaccine
Study: 34582903
Drug: Esmolol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (1.5 mg/kg bolus followed by 0.1 mg/kg/min infusion)
Study: 34582903
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Study: 32711541
Drug: β‐alanine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐alanine supplementation (4.8 g/day for 6 weeks)
Study: 33754187
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg
Study: 33754187
Drug: Niraparib 300
Normalized name: niraparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 300 mg
Study: 35257058
Drug: Low-dose roxadustat
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose roxadustat (∼1–1.4 mg/kg)
Study: 35257058
Drug: Standard-dose roxadustat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose roxadustat (∼1.5–2 mg/kg)
Study: 39282913
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg daily)
Study: 35553816
Drug: Dox (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dox (5 mg/kg/week)
Study: 35553816
Drug: Es-Exos (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Es-Exos (50 ug/animal/twice a week)
Study: 35553816
Drug: MEF-Exos (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEF-Exos (50 ug/animal/twice a week)
Study: 33069281
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg vaccine
Study: 33069281
Drug: 4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg vaccine
Study: 33069281
Drug: 8 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 μg vaccine
Study: 33069281
Drug: 8 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 μg vaccine on day 0
Study: 33069281
Drug: 4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg vaccine on days 0 and 14
Study: 33069281
Drug: 4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg vaccine on days 0 and 21
Study: 33069281
Drug: 4 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg vaccine on days 0 and 28
Study: 38171625
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg daily
Study: 34914037
Drug: Glycerol levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol levels in brain and subcutaneous adipose tissue measured through microdialysis.
Study: 38310261
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg every 4 weeks
Study: 34719872
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks
Study: 34719872
Drug: guselkumab (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab (placebo group crossover to guselkumab 100 mg every 4 weeks at week 24)
Study: 34776002
Drug: Vitamins A,
Normalized name: vitamins A,C,and D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins A, B, C, D, and E supplementation (25,000 IU daily of A, 600,000 IU once of D, 300 IU twice daily of E, 500 mg four times daily of C, one amp daily of B complex for 7 days)
Study: 34973154
Drug: L-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6 g/day for 3 months)
Study: 35675606
Drug: Clindamycin 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 2% gel
Study: 34551584
Drug: Lumateperone 42
Normalized name: lumateperone 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumateperone 42 mg/day
Study: 36154666
Drug: Throat spray
Normalized name: Throat Spray-Red
Approvals — FDA: no, EMA: no, PMDA: no
Description: Throat spray with selected Lactobacilli (verum group, n=41)
Study: 32580841
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 0.1mg/kg intravenous injection 10 mins before anesthesia induction
Study: 32580841
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml intravenous injection
Study: 35562327
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg) + Docetaxel (60 mg/m) or Pemetrexed (500 mg/m)
Study: 35562327
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m) or Pemetrexed (500 mg/m) without gefitinib
Study: 34387527
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser therapy plus 4% hydroquinone (HQ)
Study: 32498620
Drug: Mavacamten, once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten, once-daily oral administration for 30 weeks
Study: 33270229
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mirror therapy)
Study: 35228490
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 200,000 IU (single dose)
Study: 32327255
Drug: Tube shunt
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tube shunt surgery (350‐mm2 Baerveldt implant)
Study: 32327255
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 minutes)
Study: 35020797
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefazolin administered before incision
Study: 33714508
Drug: Deep dry
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep dry needling technique + routine physical therapy
Study: 86073140
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (1 mg) plus sodium glycocholate (15 mg)
Study: 33827145
Drug: Supporters' involvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supporters' involvement in therapy
Study: 33196155
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once daily)
Study: 35352600
Drug: CBIA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBIA + CC (app-based cognitive-behavioral intervention supplemented with telephone conference calls)
Study: 32107160
Drug: Reiki intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reiki intervention applied preoperatively, details on dosage and duration not available.
Study: 34036355
Drug: Zinc-biofortified wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-biofortified wheat (10.9 mg zinc/d, 0.6 g total phytate/d)
Study: 34036355
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg/d) in MP3
Study: 36104135
Drug: Maximal surgical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal surgical resection followed by chemoradiotherapy plus adjuvant chemotherapy for 6 months with neoadjuvant chemotherapy
Study: 36104135
Drug: Maximal surgical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal surgical resection followed by chemoradiotherapy plus adjuvant chemotherapy for 6 months with extended adjuvant chemotherapy until progression
Study: 36104135
Drug: Maximal surgical
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal surgical resection followed by chemoradiotherapy plus adjuvant chemotherapy for 6 months
Study: 36104135
Drug: Extended adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended adjuvant chemotherapy until progression
Study: 34311119
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for sleep disturbance and fatigue (CBT‐SF)
Study: 35418091
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (2 capsules/day for 6 weeks containing L.acidophilus, L.plantarum, L.fermentum, L.Gasseri, and fructo-oligo-saccharides)
Study: 35698099
Drug: Communication Bridge™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication Bridge™ intervention (dyadic intervention based in communication participation therapy models)
Study: 35698099
Drug: Control intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control intervention (non-dyadic intervention based in impairment therapy models)
Study: 34303862
Drug: Bayesian two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian two-stage adaptive design for MinED-based dosing-finding trials
Study: 33362392
Drug: Postoperative early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative early enteral nutrition (EEN) + parenteral nutrition (PN)
Study: 34704711
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL normal saline
Study: 34704711
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL normal saline
Study: 32660833
Drug: 12 mg⋅day−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg⋅day−1 astaxanthin for 7 days
Study: 32785021
Drug: Muscle5 supplement
Normalized name: Hippoglossus hippoglossus muscle
DrugBank: Atlantic halibut (DB15549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle5 supplement (M5) with home-based resistance exercise (HBRE)
Study: 34825640
Drug: Rehabilitation exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation exercises (REs) of lower limbs and instructions of daily care (ID-C) for 12 weeks
Study: 34825640
Drug: Instructions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions of daily care (ID-C) only for 12 weeks
Study: 34759239
Drug: Pudendal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal nerve block with 5 mL bupivacaine 0.5% with adrenaline 1:200,000
Study: 34915106
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g protein water control (WC)
Study: 34915106
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g low-dose protein (LP)
Study: 34915106
Drug: 50.0 g
Normalized name: ALCOHOL 350.0 g in 500 mL TOPICAL GEL [Clean And Fresh S]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.0 g high-dose protein (HP)
Study: 34915106
Drug: Dose-rising protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-rising protein beverage
Study: 32726566
Drug: 6% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% CHO MR solution
Study: 32246728
Drug: Low ascending
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ascending doses of oral NTX (NTX/BUP, n=50)
Study: 32246728
Drug: Low ascending
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low ascending doses of oral NTX (NTX/BUP)
Study: 35513899
Drug: Once-daily fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15%, and timolol maleate 0.5%
Study: 35513899
Drug: Twice-daily fixed
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily fixed combination of bimatoprost 0.01%, brimonidine tartrate 0.15%, and timolol maleate 0.5%
Study: 35513899
Drug: Once-daily fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily fixed combination